SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Bouillon K)
 

Search: WFRF:(Bouillon K) > Population pharmaco...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003830naa a2200445 4500
001oai:DiVA.org:uu-146987
003SwePub
008110222s2008 | |||||||||||000 ||eng|
024a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1469872 URI
024a https://doi.org/10.1111/j.1399-6576.2008.01579.x2 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Enlund, Matsu Uppsala universitet,Centrum för klinisk forskning, Västerås,Anestesiologi och intensivvård4 aut0 (Swepub:uu)matsenlu
2451 0a Population pharmacokinetics of sevoflurane in conjunction with the AnaConDa® :b toward target-controlled infusion of volatiles into the breathing system
264 c 2008-03-13
264 1b Wiley,c 2008
338 a print2 rdacarrier
520 a Background: The Anesthetic Conserving Device (AnaConDa (R)) uncouples delivery of a volatile anesthetic (VA) from fresh gas flow (FGF) using a continuous infusion of liquid volatile into a modified heat-moisture exchanger capable of adsorbing VA during expiration and releasing adsorbed VA during inspiration. It combines the simplicity and responsiveness of high FGF with low agent expenditures. We performed in vitro characterization of the device before developing a population pharmacokinetic model for sevoflurane administration with the AnaConDa (R), and retrospectively testing its performance (internal validation). Materials and methods: Eighteen females and 20 males, aged 31-87, BMI 20-38, were included. The end-tidal concentrations were varied and recorded together with the VA infusion rates into the device, ventilation and demographic data. The concentration-time course of sevoflurane was described using linear differential equations, and the most suitable structural model and typical parameter values were identified. The individual pharmacokinetic parameters were obtained and tested for covariate relationships. Prediction errors were calculated. Results: In vitro studies assessed the contribution of the device to the pharmacokinetic model. In vivo, the sevoflurane concentration-time courses on the patient side of the AnaConDa (R) were adequately described with a two-compartment model. The population median absolute prediction error was 27% (interquartile range 13-45%). Conclusion: The predictive performance of the two-compartment model was similar to that of models accepted for TCI administration of intravenous anesthetics, supporting open-loop administration of sevoflurane with the AnaConDa (R). Further studies will focus on prospective testing and external validation of the model implemented in a target-controlled infusion device.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Anestesi och intensivvård0 (SwePub)302012 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Anesthesiology and Intensive Care0 (SwePub)302012 hsv//eng
653 a anesthetics volatile
653 a sevoflurane
653 a equipment
653 a heat and moisture exchanger
653 a pharmacokinetics
653 a models
653 a target-controlled infusion
653 a Anaesthetics and intensive care
653 a Anestesiologi och intensivvård
700a Kietzmann, D.u Uppsala universitet,Anestesiologi och intensivvård4 aut
700a Bouillon, T.4 aut
700a Zuechner, K.4 aut
700a Meineke, I.4 aut
710a Uppsala universitetb Centrum för klinisk forskning, Västerås4 org
773t Acta Anaesthesiologica Scandinavicad : Wileyg 52:4, s. 553-560q 52:4<553-560x 0001-5172x 1399-6576
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-146987
8564 8u https://doi.org/10.1111/j.1399-6576.2008.01579.x

Find in a library

To the university's database

Find more in SwePub

By the author/editor
Enlund, Mats
Kietzmann, D.
Bouillon, T.
Zuechner, K.
Meineke, I.
About the subject
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Clinical Medicin ...
and Anesthesiology a ...
Articles in the publication
Acta Anaesthesio ...
By the university
Uppsala University

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view